Exhibit 2

E-SERVICE
61153558
Sep 22 2017
04:50PM
File & ServeXpress™

Northwell Health
Occupational Medicine, Epidemiology and Prevention

September 22, 2017

Donald Blydenburgh, Esq.
Levy Konigsberg, LLP
800 Third Avenue, 11th Floor
New York, New York 10022

Re: Helene Kohr

Dear Mr. Blydenburgh:

I am writing to report the results of my evaluation of the materials listed below pertaining to Ms. Helene Kohr. I have reviewed these materials in the context of my pre-existing knowledge, training, and experience in the field of occupational medicine. These materials are of the type I and other specialists in occupational medicine normally rely upon and are sufficient to form a reliable basis for my opinions contained within this report. All of the opinions stated in this report are given within a reasonable degree of medical certainty.

This report and the opinions stated in the report are based on the listed materials and my 25 years of training, education, and experience in the area of asbestos-related occupational medicine. Over the past 25 plus years, I have had the opportunity to evaluate and treat hundreds of patients with asbestos exposure, many of whom have asbestos related diseases.

Qualifications:

I am a physician licensed in the State of New York, specializing in the field of occupational and environmental disease. I have been a practicing physician since I graduated from medical school in 1988.

I attended the University of Chicago and received a Bachelor of Arts degree with Honors, with a major of History, Philosophy and Social Studies of Science and Medicine. I then continued at the University of Chicago – Pritzker School of Medicine, where I obtained my medical degree in 1988. I was elected to the Alpha Omega Alpha Honor

Society, and was also awarded an American Medical Women's Association Award. Following medical school graduation, I was an intern and resident in Internal Medicine at Yale University – Yale New Haven Hospital from 1988 – 1991. Upon completion of my Internal Medicine Residency program, I completed a second residency at the Mount Sinai School of Medicine in Occupational Medicine, from 1991 – 1993. During my Occupational Medicine Residency Program, I obtained my Master of Science Degree in Community Medicine (equivalent degree to a Masters of Public Health) in 1993. I began to evaluate dozens of patients with asbestos exposure during my residency program at Mount Sinai. I am board certified in Occupational Medicine and in Internal Medicine. I have become recertified in Internal Medicine two times.

Following completion of my residency training in Occupational Medicine, I was awarded a Fellowship in Occupational Medicine from the Foundation for Occupational Health and Research. I continued at Mount Sinai, where I joined the faculty, and continued to evaluate patients with asbestos exposure. I became Vice Chair of the Department of Preventive Medicine in 2001. I was Director of the New York/New Jersey Education and Research Center from 2006 – 2010, and had been Director of the Residency Program in Occupational Medicine from 1998-2006. I was also the Director of the Mount Sinai World Trade Center Medical Monitoring and Treatment Program from 2006 – 2010, although my involvement with the World Trade Center medical programs started in 2001, when I began to evaluate patients with exposure to the World Trade Center disaster, and was initially Medical Core Director of the World Trade Center Worker and Volunteer Medical Screening Program (2002-2004), and Co-Director of the World Trade Center Medical Monitoring and Treatment Program (2004-2006). I have published over fifty articles in the peer-reviewed literature.

In 2010, I left the Mount Sinai School of Medicine to become the Founding Chair of the Department of Population Health at Northwell Health and Hofstra Northwell School of Medicine (formerly known as North Shore University Health System). The Department changed its name in 2014 to Occupational Medicine, Epidemiology and Prevention.

I have evaluated hundreds of patients with asbestos exposure in my career in occupational medicine, spanning over 25 years. I currently direct the Occupational and Environmental Medicine Center of Long Island, providing occupational health services to patients in the metropolitan New York area. Over the past year alone, I have supervised the examination of or directly examined nearly 600 patients with asbestos exposure, as we have greatly expanded our clinical services. Over the course of the past 25 years, I have evaluated dozens of patients with malignant mesothelioma and lung cancer due to asbestos exposure. I have kept abreast of the scientific and medical literature regarding the diagnosis and causation of mesothelioma. I have personally evaluated cases of mesothelioma where the exposure was brief, and have also seen cases of mesothelioma in individuals whose only exposure to asbestos was from family members who worked with asbestos and brought their asbestos contaminated clothes home.

Materials Reviewed:

I have had the opportunity to review the medical records and deposition transcripts related to Ms. Kohr. I was provided with the following information:

1. Rush University Medical Center – Pathology Reports
2. Advocate Lutheran General Hospital – Medical Records
3. Evanston Kellogg Cancer Center – Medical Records
4. Medical Care Group – Medical Records
5. Northshore Hospice – Medical Records
6. North Shore University Health System, Evanston Hospital – Path Records
7. Rush University Medical Center – Medical Records
8. Rush University Medical Center – Pathology Reports
9. University Health System, Evanston Hospital – Medical Records
10. Plaintiffs' Certified Responses to Defendant's Master Interrogatories
11. Video Deposition of Harvey Kohr, dated February 27, 2017
12. Video Deposition of Marilyn Mason, dated February 3, 2017
13. Deposition of Elisa Kohr, dated March 30, 2017
14. Deposition of Sheryl Salzman, dated March 31, 2017
15. Death Certificate
16. Expert Report of Dr. Steven Compton, dated September 13, 2017

Ms. Kohr's Medical and Exposure History:

Clinical History: Ms. Kohr was an 81 year old woman who was in her usual state of health until she developed worsening dyspnea on exertion, fatigue, and significant weight loss. She had lost around 12 pounds by August 2015 and an additional 9 pounds (total 19 pounds compared to 2014) by October 12, 2015. Ms. Kohr went to see her primary care physician, Dr. Laura LaFave, on October 12, 2015. She noted shortness of breath over the prior few weeks. Dr. LaFave noted decreased breath sounds in the right base. Dr. LaFave ordered a chest x-ray. The chest x-ray showed a right pleural effusion and hydropneumothorax.

A CT scan of the chest on October 16, 2015 showed a 5.4 x 5.7 centimeter lung mass with pleural nodularity and a moderate to large right pleural effusion with right hydropneumothorax. Multiple small mediastinal lymph nodes were present. An enlarged anterior mediastinal lymph node was seen. Ms. Kohr had a fine needle biopsy and thoracentesis with one liter of fluid removed on October 22, 2015. The biopsy showed a malignant epithelioid neoplasm. The cytological review of the fluid showed malignant cells present, suggestive of mesothelioma.

Dr. Michael Liptay, a thoracic surgeon, saw Ms. Kohr on October 29, 2015. She had improved breathing after the thoracentesis but it had recently worsened. She noted overall fatigue and had noted a 25-pound weight loss over the prior six months. Dr.

Liptay noted that the pathology was uncertain from the fine needle aspiration and planned a right video thoracoscopy (VATS), drainage of the effusion, biopsy, and talc pleurodesis.

Ms. Kohr was admitted to Rush University Medical Center on November 2, 2015. Dr. Liptay performed a flexible bronchoscopy that showed no endobronchial lesions. He removed 500 cubic centimeters of fluid from the right chest. He noted gross nodular tumor involvement of the visceral and parietal pleura. He took several biopsies and then insufflate talc into the chest. Ms. Kohr had no post-operative complications and she was discharged on November 5, 2015. Her oxygen saturation on room air was 88% and decreased to 82% with ambulation. She was placed on supplemental oxygen at the time of discharge. The pathology showed malignant mesothelioma, epithelial cell type. The cytological review of the pleural fluid showed rare atypical cells consistent with involvement with mesothelioma.

Ms. Kohr returned for a follow-up visit to Dr. Liptay on November 12, 2015. A chest x-ray done that day showed no significant pneumothorax, but there was an accumulation of pleural fluid, equaling a small to moderate pleural effusion. There anterior pleural masses seen up to 6 x 4.5 centimeters and a 1.5 centimeter soft tissue pulmonary nodule. Scoliosis was also seen. Dr. Liptay noted she had fatigue and mild dyspnea with activity, and referred her to oncology for further care with single agent Pemetrexed.

Dr. Nicholas Campbell, a medical oncologist, saw Ms. Kohr on November 23, 2015, for treatment of her stage III, T3N1M0 mesothelioma. She had pain at the surgical site that was worse with deep breaths or movement. The pain radiated around her chest. She had insomnia, lack of energy, and decreased appetite with worsening fatigue. Dr. Campbell planned chemotherapy with platinum/Pemetrexed. He did not recommend surgery or radiation unless it was targeted at a specific location such as a portal site. Ms. Kohr returned to Dr. Campbell on November 27, 2015 to start chemotherapy. However, her performance status had declined. She was spending most of the day sleeping. Ms. Kohr elected not to receive chemotherapy and was referred to hospice care. She was enrolled in Northshore Hospice on November 29, 2015.

No additional medical records were available for my review. Ms. Kohr died on January 18, 2016. She was 81 years old.

Past Medical History: Ms. Kohr had left breast cancer and uterine (endometrial) cancer. She was treated with radiation for the breast cancer in 1999. She had surgery for the endometrial cancer in 2011. She had lumbar radiculopathy and a laminectomy in 2000, chronic hepatitis C, diverticulosis, hypercholesterolemia, and hypertension.

Cigarette Smoking History: Ms. Kohr smoked Chesterfield cigarettes starting as a pre-teen and teenager. She started smoking Kent cigarettes in 1952 and continued to smoke Kent until the 1970s. She smoked both regular and King Size Kent cigarettes. She smoked one to two packs of cigarettes per day while she was smoking Kents. In the

1970s until the mid-1980s, Ms. Kohr smoked approximately two packs of cigarettes a day. She quit in the mid-1980s. She had an approximate 50-60 pack-year smoking history. Ms. Kohr's husband recalled that she was smoking a cigarette the first time he met her in 1955, and she was smoking Kent cigarettes. Ms. Kohr's sister, Marilyn Mason, recalled Ms. Kohr smoking Kent cigarettes starting in 1952; Ms. Mason also smoked Kent cigarettes.

Occupational and Environmental History: Ms. Kohr used talcum powders from the 1950s until the 1990s. She used Cashmere Bouquet, Coty Airspun and Helena Rubinstein. Mr. Kohr recalled that Ms. Kohr used Cashmere Bouquet on her daughters when she changed their diapers. She also applied the Cashmere Bouquet to her body. Mr. Kohr recalled that she applied the powder after her shower daily in her bathroom, and there would be residual powder present. He also recalled applying powder to his daughters after their baths when they were older. Mr. Kohr believed his wife used Cashmere Bouquet until the 1980s. Ms. Mason recalled that her sister used the Cashmere Bouquet powder when they were living together at home prior to their marriages. Ms. Mason also recalled that she used both Johnson and Johnson baby powder and Cashmere Bouquet on her children. Ms. Kohr's daughters recalled her using Coty Airspun face powder and applying it to her face. Ms. Kohr used a powder puff to apply the powder. Elisa Kohr noted that the bathroom was always dusty as a result of her mother's use of the face powder. Elisa Kohr recalled that her mother used Cashmere Bouquet powder. Ms. Kohr switched to a compact face powder in the 1980s. Her daughter Sheryl Salzman also remembered that her mother used the Coty Airspun Face powder on a regular basis. Ms. Salzman recalled that her mother used the Coty face powder from 1963 or 1964 until the late 1970s. Her mother applied the powder every morning and in the evenings if her mother were going out. She would put powder on the velour puff, tap the powder and then apply it to her face. Ms. Salzman recalled that her mother used Cashmere Bouquet after taking a shower. She also noted that her parents would use Cashmere Bouquet when changing the diapers of her younger sisters, and that they shook the powder onto the babies. Ms. Salzman noted that her mother would shake the powder on her legs and then use a white powder puff to apply it to her chest and under her arms. Ms. Kohr also applied Cashmere Bouquet inside her girdle which her daughter recalled made it easier to get the girdle on.

Ms. Kohr worked in office jobs and at a tape supplier/re-seller. She has no known occupational exposure to asbestos.

Conclusion: Ms. Kohr had malignant mesothelioma of the pleura as a result of her exposure to asbestos from Kent cigarettes and cosmetic talc. She underwent diagnostic surgery, but elected not to receive palliative chemotherapy.

Based on the information available, it is my opinion, to a reasonable degree of medical certainty that Ms. Kohr's exposure to asbestos-containing Kent cigarettes, talcum powder, and asbestos-containing facial powder led to the development of her mesothelioma. She began smoking Kent cigarettes when the Micronite filter was introduced in 1952 and continued with this brand for years after the Micronite filter was

discontinued, but smoked during the entire time period that crocidolite asbestos was included in the filter of the cigarettes (1952-1956). She used Cashmere Bouquet talcum powder starting in the 1950s and Coty Airspun face powder in the 1950s and continued to use it until the 1980s.

The methodology and basis for my opinions follows standard methods of the medical and scientific community. Asbestos is the most well known cause of mesothelioma, and the causation of mesothelioma has been established by the quantitative history of exposure to asbestos. Thousands of individuals, from myriad professions and exposure situations have developed mesothelioma as a result of either direct or indirect exposure to asbestos. The reliance on the history of exposure to asbestos was used by seminal studies by Newhouse, Wagner and Selikoff in the 1960s, who attributed mesothelioma to asbestos exposure based solely on the history of exposure. The increased risks for mesothelioma exist for individuals who both worked directly with asbestos products and for those who worked adjacent to or in the vicinity of others who were using asbestos products, which is known as "bystander" exposure.

Asbestos and Malignant Mesothelioma General Opinions: Occupational Medicine is the field of medicine that deals with exposures to substances, toxins, conditions and agents in the workplace that are associated with increased risks of diseases. It exists as a subspecialty of Preventive Medicine that deals with identifying ways to prevent people from becoming ill. This includes identifying the sources, agents or catalysts that increase the likelihood of someone developing a disease, illness, or detrimental condition, and educating people on how to eliminate, avoid, and/or mitigate those risks. To put it simply, Occupational Medicine and Preventive Medicine involves searching for and identifying causes of diseases. This knowledge is important for those who are already ill: elimination of the catalysts can eliminate or mitigate the illness. It is also important from a public health point of view: to a large extent, the higher purpose of Occupational Medicine and Preventive Medicine is to educate and warn the public on how to eliminate, avoid, or mitigate the risks of diseases at the workplace, and to provide guidance to governments and businesses on appropriate regulations and standards concerning workplace health and safety.

One of the essential tasks of a physician of Occupational Medicine, when dealing with an individual patient, is the taking of a proper occupational history. Standard medical histories usually involve the patient explaining their reason for seeking medical attention; a listing of current symptoms, conditions, allergies, medications and other relevant medical problems; and providing some family and social history. Occasionally, a standard medical history may-but doesn't always-include identifying the patient's occupation.

A full occupational history, on the other hand, will go into details of a patient's entire work history, including details concerning their tasks and duties and their working conditions and environment. The history will also routinely make inquiries into the patient's home or hobbies. It would also reveal what kinds of substances or agents the patient was exposed to in his or her working environment that might have occurred

decades earlier. It remains the standard tool for determining exposure and has not been supplanted by quantitative measurements, which are rarely obtained, and would not, unless continuously performed on an individual (which is not feasible), fully address all exposures an individual might have had. At times, it is not possible to directly obtain an occupational history from an individual, and information concerning work and environmental experiences contained in deposition transcripts by plaintiffs, co-workers and family members can provide detailed information of that type that can be elicited from an occupational physician-obtained history.

The hallmark of occupational medicine is to connect an exposure to a hazardous substance to a disease, and identify whether there is a causal relationship. This is a critical differentiation in the field of occupational medicine; not only do we treat patients for disease, but we emphasis what hazardous substance might be causing the disease. In occupational medicine training, there are core areas of training, including epidemiology, biostatistics, toxicology, and industrial hygiene.

Asbestos and Disease: Asbestos is a naturally occurring mineral that has been used commercially for a variety of purposes for over 100 years. Asbestos is mined in the form of microscopic fibers released from the surrounding earth. Asbestos was extremely useful from an industrial perspective: it is highly resistant to heat and therefore serves as an excellent insulator and friction surface. It is also very durable, and as a fiber it can be molded into shapes and products that serve a variety of functions. However, asbestos is also highly toxic and carcinogenic when the fibers are inhaled or ingested.

While there are many "fiber types" of asbestos, as well as different sizes of the fibers, there exists consensus among scientists that exposure to *any* asbestos fiber type or size increases the likelihood of lung cancer, mesothelioma, as well as nonmalignant lung and pleural disorders. Asbestos fibers are generally divided into two categories: amphiboles and serpentine (or chrysotile). There are several varieties of amphiboles, including both commercial and non-commercial types. The three major asbestos types used in industry have been chrysotile, amosite and crocidolite. Of these three fiber types, over 95% of all asbestos used in the United States has been chrysotile. Much of the chrysotile asbestos that was used in the US was mined in Canada, where there was contamination with small amounts of tremolite, another type of amphibole asbestos. The mainstream scientific community has also long recognized, and continues to recognize today, that there is no "safe" level of exposure to asbestos regardless of fiber type or size. This position is shared by numerous United States government agencies, including the Occupational Safety and Health Administration ("OSHA", which has regulatory authority over workplaces), the Environmental Protection Agency ("EPA" which has regulatory authority over non-occupational settings), the National Institute for Occupational Safety and Health ("NIOSH", which is responsible for conducting research and making recommendations for the prevention of work-related injuries and illnesses), the World Trade Organization ("WTO"), and the national academies of science of every major industrialized nation. The World Health Organization recently reviewed the existing literature and concluded (in 2014) that all fiber types are capable of causing asbestos

related disease, including mesothelioma, and reiterated the statement that there is no safe level for exposure to asbestos.

Due to the ubiquitous use of asbestos and its presence in naturally occurring formations, there is asbestos in the ambient air in the United States, albeit at minute levels. The ambient air concentration or "background level" has been reported to range from 0.0005 f/cc in urban areas, to 0.00005 f/cc in rural regions. These levels are thousands of times less than the current OSHA permissible exposure level of 0.1 f/cc. While it is theoretically possible to develop mesothelioma from ambient air concentrations, it has not been proven to occur at levels at or below ambient air concentrations. Given that there is no truly "unexposed" population, it would be impossible to reasonably perform such a study to determine if this were the case.

State of the Art:
In 1898 Montague Murray described interstitial fibrosis in an individual exposed to asbestos. Pancoast described radiographic changes of interstitial fibrosis in asbestos workers in 1917. Cooke described two cases of asbestosis in the 1920s, and actually used the term "asbestosis" to describe the interstitial fibrosis among asbestos workers, and also noted pleural plaques (fibrosis) in these workers.

In 1930 Merewether and Price, in their *Report on the Effects of Asbestos Dust on the Lungs and Dust Suppression in the Asbestos Industry*, noted that inhaling dust containing asbestos fibers could lead to disabling and fatal lung disease. They studies asbestos workers in the textile mills in Great Britain, and noted that asbestosis could occur in large numbers of exposed individuals. Moreover, they found that the textile workers with the highest exposures had more asbestosis than workers in areas where asbestos exposure was lower. Merewether and Price noted that asbestos was a potential hazard to health in any industry where dry asbestos products were abraded or otherwise manipulated to generate dust, such as thermal insulating. They recommended warning, education and training of all those individuals who were exposed to asbestos.

Lynch and Smith noted a case of lung cancer in an asbestos worker from South Carolina in 1935. Textbooks in the 1930s, such as A.J. Lanza's textbook on dust disease, included asbestosis as a disease of concern. In 1943, the first case of mesothelioma was associated with asbestos exposure and was published by Wedler in Germany. Also in 1943, Hueper from the United States Public Health Service stated that he believed asbestos caused lung cancer. He published an editorial stating this association in the Journal of the American Medical Association in 1949.

In 1955, Doll published a seminal article that described the increased risk of lung cancer among asbestos exposed workers. By the time of Doll's epidemiology study, there had been over 60 cases of asbestos-related lung cancer published in the literature. In 1960, Wagner et.al. published a study of 33 cases of malignant mesothelioma among individuals who were exposed to asbestos in and around the crocidolite mines in South Africa. Not only were miners developing disease, but family members, individuals on the wagon routes in which the asbestos was carried and people who had played with mine

tailings as children developed mesothelioma. In the early 1960s numerous studies in several countries, under different exposure scenarios, were published that showed mesothelioma in association with asbestos exposure. In fact, by the end of 1964, over 700 scientific articles had been published that showed the adverse health effects of asbestos.

The Development of Diseases: When asbestos is inhaled, some proportion of the fibers can be deposited upon any component of the respiratory tract, including the nose, pharynx, conducting airways and the alveolar or gas exchanging regions of the lung. Fibers that land initially on the airways and above are cleared rapidly from the lung. The primary defense mechanism that mediated this clearance is known as the mucociliary escalator. The escalator is comprised of collated and mucous producing epithelial cells that propel inhaled fibers up to the mouth where they can be swallowed or expectorated. These epithelial lining cells are the "target cells" for cancers. Fibers that evade the mucociliary escalator can penetrate into the lower airways and lung tissue, where they can be transported through the body. Amphibole fibers tend to clear from the lung less rapidly than chrysotile fibers. Asbestos is cleared through the pulmonary lymphatics to lymph nodes and to the pleura, the target organ for pleural mesothelioma. Of the different fiber types, Suzuki, Sebastien and LeBouffant have all shown that chrysotile fibers preferentially translocate to the pleural space.

Asbestosis: The fibers that are inhaled and deposited past the escalator can cause asbestosis. These fibers deposit initially on the Type 1 and Type 2 alveolar epithelial cells. On the epithelial surfaces, some asbestos fibers activate the 5th complement which attracts inflammatory cells, including foreign particles, like asbestos, from the lung. About 20% of the fibers deposited on the alveolar surfaces are enveloped by the Type 1 cells and are translocated to the underlying connective tissue (interstitial) compartment. There, the fibers can interact with interstitial fibroblasts, myofibroblasts and macrophages. Fibroblasts and myofibroblasts are the target cells for asbestos because these are the cells that synthesize and release the scar tissue matrix. (See Y. Suzuki & N. Kohyama, *Translocation of Inhaled Asbestos Fibers from the Lung to Other Tissues.*,19 Am J. Indus, Med. 701 (1990); Y. Suzuki & N. Kohyama, *Translocation of Inhaled Asbestos Fibers from the Lung to Other Tissues*., *19* Am J. Indus, Med. 701 (1991)). They produce scar tissue when the epithelial cells are injured and when the macrophages are activated. Alveolar cells and macrophages release a number of protein growth factors that stimulate the fibroblasts to multiply and produce scar tissue and the fibroblasts and myofibroblasts also synthesize a similar array of factors that induce their own cell growth and matrix production that we recognize as asbestosis. Like *all* of the asbestos-related diseases, asbestosis is dose dependent. An individual typically needs long-term occupational exposure to develop clinical asbestosis.

The scarring process described above begins as soon as inhaled fibers are deposited on the alveolar surfaces, and microscopic asbestosis is ongoing in the lungs of afflicted individuals for many years before any clinical signs or symptoms are presented. The initial physiological symptom of asbestosis is shortness of breath. This is caused by the scar tissue which replaces normal elastic connective tissue, this producing a stiff lung that restricts the individual from taking a deep breath. Shortness of breath also results

when scar tissue thickens the alveolar-capillary membrane, the barrier across which oxygen and carbon dioxide gases are exchanged.

Pleural Plaques and Fibrosis: This is scar tissue formation in an identical manner to that described above, under asbestosis. The difference is that there is little direct deposition of asbestos fibers in the pleura. While some fibers can be inhaled through the alveolar ducts and reach the pleura directly, most fibers that land on alveolar surfaces and reach the interstitial compartment have direct access to the pleura do so by way of pulmonary lymphatic flow. The inhaled fibers that land on alveolar surfaces and reach the interstitial compartment have direct access to lymphatic fluids which flow through these regions on the way to the pleura. The lymphatic flow carries fibers to the pleura where they interact with the sub-mesothelial fibroblasts that produce a scar tissue matrix, as described above. If the scarring is in a circumscribed pattern, the scarring is called "plaque". Investigators have shown that this injury can result in a restrictive lung disease in some individuals.
Lung Cancer: These tumors caused by asbestos typically arise in cigarette smokers, although some epidemiologic studies on asbestos-exposed non-smokers show an increased risk of developing the disease. When an individual is exposed to the cancer-causing agents (carcinogens) of both cigarettes and asbestos, the risk of getting lung cancer is increased well beyond the risk presented by exposure to either agent alone or by simply adding the risks of the two carcinogens. Epidemiologists multiply the risks of the two carcinogens since there is a clear synergy in the way asbestos and cigarette smoke combine to cause lung cancer.

Cancer is the loss of control of cell growth. Every cell in the bodies of humans and animals is under strict genetic control of the rate at which a given cell replaces itself by dividing. Cancer is caused when the specific genes that control cell division and other aspects of the cell cycle develop errors or mutations. Carcinogens induce such errors, and complete carcinogens can produce the errors with no other agent required. Cigarette smoke has a number of complete carcinogens, and all of the asbestos varieties have been shown to act as complete carcinogens. Thus, as the airway epithelial cells of the mucociliary escalator are assaulted daily by cigarette smoke and asbestos fibers, a number of cells are injured, and many exhibit genetic errors through the lifespan of the individual. In those who are susceptible to developing a cancer, one of those injured cells accumulates a sufficient number of genetic errors in genes that control cell growth to finally, after decades of exposure, lose the normal growth pattern and grow into a malignant tumor. (See Frost G, Darton A, Harding AH. *The effect of smoking on the risk of lung cancer mortality for asbestos workers in Great Britain (1971-2005)* Ann Occup Hyg 55:239-24 (2011)).

Mesothelioma: This cancer occurs when a mesothelial cell of the pleural or peritoneal surfaces develops a sufficient number of genetic errors in a set of genes that control cell growth, as described above. Cigarette smoking has no influence on the development of mesothelioma. (See N.S. Offermans, et. al., *Occupational Asbestos Exposure and Risk of Pleural Mesothelioma, Lung Cancer, and Laryngeal Cancer in the Prospective Netherland Cohort Study,* 56 J. Occupational Envt'l Med. 1 (2014); Robinson BM.

Malignant pleural mesothelioma: an epidemiological perspective, 1 Annals Cardiothoracic Surgery 491 (2012)).

Asbestos exposure is the only known occupational and/or environmental cause of mesothelioma in North America, and all of the asbestos varieties induce the genetic errors described above and cause this cancer. The fibers that cause mesothelioma reach the pleural surfaces through the lymphatic pathways, as explained earlier, and they interact with the target cells of the mesothelial surfaces. When a sufficient number of genetic errors have accumulated in a single mesothelial cell, this cell can undergo neoplastic transformation and grow into a deadly tumor. It typically takes many decades for a sufficient number of mutations to occur in a single mesothelial cell because of the numerous effective defense mechanisms that destroy genetically defective cells, thus explaining the long latencies known for this cancer.

All of the asbestos varieties have been shown to cause genetic errors and fibers less than five microns can bind DNA and this contributes to the development of genetic damage. Short fibers have been found to accumulate in the pleural regions of the lung as well as in mesenteric lymph nodes of the peritoneal cavity. Longer fibers may be comparatively more dangerous than short fibers (on a fiber per fiber basis), but all size ranges are capable of causing and contributing to the development of mesothelioma or any of the asbestos-related diseases. Exposure to asbestos fibers of all types and lengths are toxic, and short fibers more readily reach the mesothelial target cells of the pleura. (See Y. Suzuki & S. R. Yeun, *Asbestos Fibers Contributing to the Induction of Human malignant mesothelioma.,* 982 Annals N.Y. Acad. Sci. (2002); Y. Suzuki, et al. *Short thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence.,* 208 Int'l. J. Hygiene Envtl. Health 201 (2005)). Fibers of all lengths can bind to DNA and cause genetic errors that are required in the causation of cancer such as mesothelioma. Fiber burden studies of mesothelioma patients show a preponderance of chrysotile asbestos within the tumor tissue. Since the target location of mesothelioma is the pleura, the lung burden of asbestos does not reflect the fact that asbestos has moved from the lung to the pleura, where it can cause the mesothelioma to develop. (See Ronald F. Dodson, *Analysis and Relevance of Asbestos Burden in Tissue, in Asbestos: Risk Assessment, Epidemiology and Health Effects.* Risk Assessment, Epidemiology and Health Effects 78 (2d, ed. 2011); M. Silverstein, et al., *Developments in Asbestos Cancer Risk Assessment.* Am J. of Indus. Med. (2009).

Moreover, there is ample evidence to support the conclusion that exposure to the asbestos fibers typically used in brake linings-chrysotile fibers-can and does cause mesothelioma. This conclusion is supported by, among others, the American Conference of Governmental Industrial Hygienists, the American Thoracic Society, the Environmental Protection Agency, the International Agency for Research on Cancer, the National Toxicology Program, OSHA, the Consumer Products Safety Commission, the World Health Organization, and the World Trade Organization. The scientific consensus that all fiber types and sizes can cause mesothelioma is also reflected in the Consensus Report of the 1997 Helsinki Conference (discussed below) and publications from the

American Cancer Society and the National Cancer Institute of the National Institutes of Health.

In essence, there exists a consensus among the overwhelming majority of medical and scientific professionals and organizations that asbestos fibers of any type or size can cause mesothelioma, including chrysotile fibers. (See Dodson, Ronald F. et al., *Asbestos Fiber Length as Related to Potential Pathogenicity: A Critical Review,* 44 Am J. Indus. Med. 291 (2003); D. Egilman, et al., *Exposing the "Myth" of ABC, "Anything But Chrysotile: A Critique of the Canadian Asbestos Mining Industry and McGill University Chrysotile Studies.* 44 Am J. Indus. Med. 540 (2003); David S. Egilman & Marion Billings: *Abuse of Epidemiology: Automobile Manufacturers Manufacture a Defense to Asbestos Liability,* 11 Int. J. Occupational Envtl Health 360 (2005). 11:360-371; Egilman D. *Fiber Types, Asbestos Potency, and Environmental Causation.* 15 Int. J. Occupational Envtl. Health (2009); Finkelstein, M. *Asbestos Fiber Concentrations in the Lungs of Brake Workers: Another Look,* 52 Annals Occupational Hygiene 455 (2008); M.M. Finkelstein & C. Meisenkothen, *Malignant Mesothelioma among Employees of a Connecticut Factory that Manufactured Friction Materials Using Chrysotile Asbestos.* 54 Annals Occupational Hygiene 692 (2010); P.J. Landrigan, et al., *The Hazards of Chrysotile Asbestos, a Critical Review.* 37 Indus. Health 271 (1999); W.J. Nicholson, *The Carcinogenicity of Chrysotile Asbestos-A Review.* 39 Indus. Health 57 (2001); R.A. Lemen, *Chrysotile Asbestos as a Cause of Mesothelioma: Application of the Hill Causation Model.* 10 (2) Int. J. Occupational Envtl. Health (2004); *see also* R. Lemen, *Asbestos in Brakes: Exposure and Risk of Disease.* 45 Am. J. Indus. Med 229 (2004); EPA: *Guidance For Preventing Asbestos Disease Among Auto Mechanics.* (1986); A.H. Smith & C.C. Wright, *Chrysotile Asbestos is the Main Cause of Pleural Mesothelioma.* 30 Am. J. Indus. Med. 252 (1996); U.S. Dept. of Labor: *Working Safely with Asbestos in Clutch and Brake Linings.* (posting); U.S. Dept. of Labor, OSHA Directorate of Science, Technology and Medicine, Office of Science and Technology Assessment. *Asbestos-Automotive Brake and Clutch Repair Work*; World Health Organization, *Environmental Health Criteria 203: Chrysotile Asbestos.* International Programme on Chemical Safety (1998 Geneva)).

Asbestos fibers are very small; so small, in fact, that millions of fibers could fill the air in a room without anyone being able to perceive it with the naked eye. The fibers are odorless, cannot be seen with the naked eye, and are aerodynamic. Consequently, someone can inhale asbestos fibers without even being aware of it. The fibers are also small enough to pass through the normal respiratory defense mechanisms that the human body uses to keep out toxins and debris.

The Scientific community has even concluded that small amount of asbestos exposure can cause cancer. The Rodelsperger study indicates that exposure to asbestos below the Occupational Safety and Health Administration (OSHA) Permissible Exposure Level (PEL) of 0.1 fibers per cubic centimeter can cause disease. However, visible asbestos-laden dust that is released into the air from the manipulation of gaskets or packing, or that is reintroduced into the respirable zone from the process of sweeping the

floor, is between 2.0 and 10.0 fibers per cubic centimeter. These levels far exceed the OSHA PEL. Some of these levels even exceed the OSHA PEL issued in 1972.

Government agencies and international organizations universally recognize asbestos as a carcinogen in low levels. These agencies include the International Agency for Research on Cancer, Environmental Protection Agency, OSHA, National Institute for Occupational Safety and Health, and World Health Organization. The inhalation of asbestos fibers also does not trigger any immediate physiological reactions: the victim doesn't experience any immediate irritation, asthmatic problems, or allergic reactions. Moreover, the latency, or development period, for mesothelioma is very long: the minimum latency period is usually considered to be around 10 years with a maximal latency period well over 60 years after the last exposure. Consequently, it could be decades before someone is aware that he or she was exposed to asbestos, or it might have occurred so remotely that they do not realize they had asbestos exposure. Moreover, they may not realize that a product they used contained asbestos and thus are unaware they had exposure.

The Helsinki Criteria for Attribution: In January 1997, a conference called "Asbestos, Asbestosis and Cancer" was held in Helsinki, Finland. The conference was convened to establish criteria for diagnosis and attribution of disorders of the lungs and pleura, including mesothelioma. This was a multidisciplinary group of internationally recognized experts, consisting of pathologists, radiologists, occupational and pulmonary physicians, epidemiologists, toxicologists, industrial hygienists, and clinical and laboratory scientists specializing in tissue fiber analysis. Collectively, the members had published over 1,000 articles on asbestos and associated disorders. The conclusions of the conference were developed into a peer-reviewed Consensus Report that established the "Helsinki Criterion". Among the conclusions of the Helsinki Criterion are:

a. That, in general, reliable work histories provide the most practical and useful measures of occupational asbestos exposure; and
b. That even in the absence of other independent evidence of disease (e.g. lung fiber counts exceeding the background range for the lab in question; the presence of radiographic or pathological evidence of asbestos-related tissue injury; histopathologic evidence of abnormal asbestos content), a history of significant occupational, domestic or environmental exposure to asbestos will suffice for attribution of the disease with asbestos exposure.

Moreover, with reference to determining an occupational etiology of mesothelioma, the Helsinki Criterion Consensus Report concluded that:

a. The great majority of mesotheliomas are due to asbestos exposure;
b. Mesothelioma can occur in cases with low asbestos exposures. However, very low background environmental exposures carry only an extremely low risk;

c. About 80% of mesothelioma patients have had some sort of occupational exposure to asbestos (necessitating a carefully obtained and detailed occupational history for proper diagnosis);
d. An occupational history of brief or low-level exposure should be considered sufficient for mesothelioma to be designated as occupationally related;
e. A minimum of 10 years from the first exposure is required to attribute mesothelioma to asbestos exposure (though in most cases, the latency interval is longer);
f. Smoking has no influence on the risk of mesothelioma.

The conclusions of the Helsinki Criterion have since been adopted by, and form the general consensus of, the medical community's positions vis-à-vis mesothelioma and asbestos. (See *Consensus Report, Asbestos, asbestosis and cancer: the Helsinki criteria for diagnosis and attribution,* 23 Scandinavian J. Work Environ Health 311 (1997)). And, given the fact that about 80% of patients with mesothelioma have had some sort of occupational exposure to asbestos,[1] asbestos exposure in the workplace is a prime focus of Occupational Medicine when dealing with mesothelioma patients.

Mesothelioma is a dose responsive disease: It is my opinion that Mesothelioma and asbestos related lung cancer are dose responsive diseases in which more substantial exposures directly increases the risk for the development of these cancers. This linear dose-response relationship presented in *Asbestiform Fibers: Non-occupational Health Risks,* published by the National Research Council National Academy of Sciences in 1984, discussed herein, is neither new nor novel and generally accepted in the medical and scientific communities. As per the aforementioned Helsinki criteria, the first question usually asked of a patient diagnosed with mesothelioma, concerns how, when, and where the patient was exposed to asbestos. (*See Consensus Report, Asbestos asbestosis and cancer: The Helsinki criteria for diagnosis and attribution.* 23 Scandinavian J. Work Environ Health 311 (1997)). Because of the proven association between asbestos fibers and mesothelioma, proof of significant exposure to asbestos dust is considered to be proof of specific causation. (*See* P. Boffetta, et al., *Health Effects of Asbestos Exposure in Humans: A Quantitative Assessment.* 89 (6) Medicina Del Lavoro, 471 (1998). This causal relationship between exposure to asbestos dust and the development of mesothelioma is so firmly established in the scientific literature that it is accepted as a scientific "fact".

Malignant mesothelioma is, in general, a dose response disease where each and every significant exposure to asbestos-containing dust has been shown to contribute to cause diffuse malignant mesothelioma including pleural mesothelioma (*See also* Newman, et al., *Malignant Mesothelioma Register 1987-1999.* 74 Int'l Arch Env. Health 383 (2001), (concluding that "higher cumulative asbestos-fiber dose leads to the earlier development of mesothelioma)). As each exposure to asbestos contributes to the total

[1] The remaining 20% of mesothelioma patient likely had asbestos exposures that were para-occupational or are simply unidentified.

amount of asbestos that is inhaled, and, in doing so, reduces the necessary period for asbestos disease to develop. Therefore, each non-trivial exposure to asbestos should be considered a substantial contributing factor in the development of the malignant mesothelioma or lung cancer.

Exposure to Asbestos contaminated talc and disease

Asbestos fibers have been reported in cosmetic talcum powder for decades, in company documents, the media, FDA communications, and the published medical and scientific literature. Cosmetic talc has been analyzed by researchers in various countries, and has routinely been shown to be contaminated with asbestos. Exposure to asbestos contaminated talc has been shown to cause asbestos related diseases, including mesothelioma. In 1976 Rohl and Langer tested 20 consumer products that had been labeled as talc or talcum powder, including body powders. Of the 20 products that were tested, ten were found to contain tremolite and anthophyllite, principally asbestiform. Of note, the product that had the highest asbestos content in the Rohl and Langer study was the same product later tested by Gordon, et.al. This product was in fact, Cashmere Bouquet, the body talcum powder used by Ms. Kohr. A recent paper by Gordon, et.al., Asbestos in Commercial Cosmetic Talcum Powder as a Cause of Mesothelioma in Women, evaluated the mineralogical constituents of Cashmere Bouquet and its ability to release asbestos fibers into the breathing zone of the direct user and bystanders. In their paper Gordon et.al. noted that the talc that was used in Cashmere Bouquet was derived from three distinct regions, where anthophyllite and tremolite asbestos were found. Gordon et.al. measured 18 million anthophyllite asbestos fibers per gram in the talcum powder. Air measurements were done by both phase contrast microscopy (PCM) and transmission electron microscopy (TEM), and significant levels of asbestos fibers were noted (anthophyllite, tremolite and some chrysotile) in the breathing zone of the individual applying the powder as well as a bystander. Results taken from the experiment in the paper show that personal measurements from the shaker container test showed a measurement by PCM of 4.8 f/cc, with an actual asbestos fiber measurement of 1.8 f/cc. Bystander measurements showed a lower, but still significant exposure of 1.35 f/cc by PCM for the bystander, and 0.5 f/cc of actual asbestos fibers. Similar measurements were done with the puff application method. Personal measurements after using a puff were 23.6 f/cc and 16.5 f/cc for the user, with actual asbestos fiber measurements of 5 f/cc and 3.5 f/cc. A short term sample showed even higher measurements, of 60 f/cc with the use of a puff and actual asbestos fiber measurements of 13 f/cc. Bystander exposures to asbestos from the puff application were elevated, with a short term sample by PCM of 13.7 f/cc and 9.7 f/cc, and an actual asbestos fiber measurement of 4.9 f/cc and 3.5 f/cc. Gordon et.al. also noted that the TEM measurements were far more sensitive than x-ray diffraction detection, since there was a much lower detection limit with TEM.

In addition to looking at bulk and air samples, Gordon et.al analyzed the lung tissue and lymph node tissue of a woman who had been exposed to contaminated talcum powder (Cashmere Bouquet). The authors found that there were 3150 and 4150 fibers per gram wet weight, respectively, with a detection limit of 690 fibers per gram wet weight. All fibers were 5 micrometers or greater in length, and had an aspect ratio of 20:1 or greater. The fibers were identified as anthophyllite or tremolite. In addition to the fibers

counted above, there were many anthophyllite and tremolite fibers that were less than 5 micrometers in length, with a predominance of anthophyllite. In the lymph node, amphibole asbestos fibers were also noted, measuring 12,738 fibers per gram wet weight (detection limit 2123 fibers per gram wet weight). Again, the fibers noted were anthophyllite and tremolite. In addition to the asbestos found in the lungs, the authors noted fibrous and platy talc and small asbestos bodies.

The issue of asbestos and talc has been studied for decades among talc miners. Lung scarring was seen in miners from New York State in the 1950s, and there are elevated rates of mesothelioma and lung cancer in miners at the asbestos contaminated talc mines. The International Agency for Research on Cancer has noted that talc contaminated with asbestos is carcinogenic.

Applying an Accepted Method for Evaluating Disease Causation in an Individual

In deciding whether Ms. Kohr's mesothelioma was caused by her exposure to asbestos, I applied the methodology that was described by Welch, et.al. in her paper Asbestos Exposure Causes Mesothelioma, but Not This Asbestos Exposure: An Amicus Brief to the Michigan Supreme Court, published in 2007 in the International Journal of Occupational and Environmental Health. In this paper, she identifies four questions that should be examined in the causation of disease in an individual:

1. Was the individual exposed to a toxic agent?
2. Does the agent cause the disease present in the individual?
3. Was the individual exposed to this substance at a level where the disease has occurred in other settings?
4. Have other competing explanations for the disease been excluded?

For question #2, there is ample literature that asbestos causes mesothelioma and no dispute in the medical literature. With respect to question #1, Ms. Kohr had an exposure to asbestos from talcum powder and facial powder for many years, fulfilling this criterion. She was also exposed to asbestos from the Kent micronite filter, which contained crocidolite asbestos from 1952 – 1956 when she was smoking one to two packs of Kent cigarettes a day. Coty Airspun face powder, Cashmere Bouquet and Kent micronite filters have been shown to contain asbestos and Ms. Kohr would have had asbestos exposure based on the descriptions from her family's deposition testimony. Apart from this potential exposure, she has no other competing explanations (#4) for the development of her mesothelioma. While she did have radiation after her breast cancer, and there is a potential connection between radiation treatments and subsequent development of mesothelioma, she underwent radiation on the contralateral (left) side; there is no evidence that radiation on the contralateral side of the body is associated with the development of mesothelioma. The remaining criterion, #3 is whether there is an analogous exposure scenario in which others also developed mesothelioma. As described above, and recently published by Gordon, et.al, there are other women with exposure to contaminated talc products who then developed malignant mesothelioma.

Summary and Specific Causation in Ms. Kohr's Case

Based on the information that was provided to me, and applying both my understanding of the medical literature and the facts of this case, it is my opinion to a reasonable degree of medical certainty that the exposures to the dust from asbestos-contaminated cosmetic talc products that Ms. Kohr used for many decades, starting over 50 years ago, were above normal background levels. In fact, Rohl, in correspondence to the FDA in the 1970s noted that Coty face powder contained 11% tremolite, and tremolite asbestos was also found when Pfizer, Inc.'s Research Department analyzed the Coty Airspun Face Powder and in more recent fiber release studies of samples of these products. The bulk analysis and fiber release studies done recently by Fitzgerald and others from ore taken from the same source mines as those used in the manufacture of the Cashmere Bouquet and Coty products showed significant amounts of chrysotile, anthophyllite, and tremolite asbestos. Ms. Kohr was exposed to asbestos from Kent Micronite cigarettes, which she smoked from 1952-1956 when crocidolite asbestos was used in the filters. Studies have shown that each filter contained 10 milligrams of crocidolite asbestos and that millions of fibers of asbestos were released into the lungs during smoking. Dr. Steven Compton has personally evaluated Kent Micronite cigarettes and noted crocidolite asbestos fibers present in the Micronite filter. Longo et al tested Kent cigarettes (Cancer Research 1995) and noted crocidolite fibers in both the filters and in the cigarette smoke itself.

Her exposures to asbestos-contaminated face powder and asbestos-contaminated body powder and to Kent cigarettes were the cause of her mesothelioma. If she had not used asbestos-containing face and body powder, nor had she smoked Kent cigarettes in the 1950s, she would not have developed malignant mesothelioma.

The opinions related to Ms. Kohr's case are based on my review of the evidence of exposure in this case, the medical and scientific literature as described above regarding asbestos exposure and disease, available studies concerning fiber release, epidemiological studies of exposure to asbestos exposure and the development of disease, and my knowledge, skill, experience, and training as a physician specializing in occupational medicine with a clinical focus on evaluating individuals with asbestos exposure.

Ms. Kohr suffered and died from metastatic malignant mesothelioma of the right pleura. She had a rapid course and died around two months after she was diagnosed.

I have attached a partial reference list that indicates reliance materials for this report.

Sincerely,

Jacqueline Moline, MD, MSc, FACP, FACOEM

REFERENCE & RELIANCE LIST
Jacqueline Moline, M.D.

1. Andrion, Alberto, et al. *Malignant Peritoneal Mesothelioma in a 17-Year-Old Boy with Evidence of Previous Exposure to Chrysotile and Tremolite Asbestos*, Human Pathology, Volume 25, No. 6 (June 1994).
2. Arul KJ, Holt PF, *Mesothelioma Possibly Due to Environmental Exposure to Asbestos in Childhood*, Int. Arch. Occup. Environ. Hlth 40, 141-143 (1977).
3. *Asbestos, Asbestosis, and Cancer: Helsinki Criteria for Diagnosis and Attribution 2014*, Finnish Institute of Occupational Health (2014).
4. *Asbestos Dust Called a Hazard To at Least One-Fourth of U.S., The New York Times* (March 2, 1966)
5. *Asbestos Fibers Found in Baby Powder*, The Washington Post, March 8, 1976.
6. *Asbestos Found in Ten Powders*, The New York Times, March 10, 1976.
7. *Asbestos: You'll Be All Right if You Just Stop Breathing, New York Times* (July 18, 1971)
8. *Atkinson*, MA., et al. *Evaluation of the Size and Type of Free Particualtes Collected from Unused Asbestos Containing Brake Components as Related to Potential for Respirability,* 46 American Journal of Indusrial Medicine, 545 (2004).
9. Azuma K, Ochiyama I, Chiba Y, Okumura J. *Mesothelioma Risk and Environmental Exposure to Asbestos: Past and Future Trends in Japan.* Int. J. Occup. Environ. Health 15:166-72 (2009).
10. Bamber HA, Butterworth R. *Asbestos hazard from protective clothing*. Ann Occup Hygi 1970, 13:77-79.
11. Barton H, et al., *Assessing Susceptibility from Early-Life Exposure to Carcinogens*, Environmental Health Perspectives 2005; 113 (9); 1125-1133.
12. Bearer C, *How Are Children Different from Adults?*, Environmental Health Perspectives, 103(Suppl 6):7-12 (1995).
13. Birnbaum L, Fenton S, *Cancer and Developmental Exposure to Endocrine Disruptors*, Environmental Health Perspectives 2003; 111 (4); 389-394.
14. Bitchatchi E., et al., *Mesothelioma and asbestosis in a young woman following occupational asbestos exposure: Short latency and long survival: Case Report*, Diagnostic Pathology, 5:81 (2010).
15. Block, L., et al., *Modernization of Asbestos Testing in USP Talc*, U.S. Pharmacopeial Convention, Stimuli to the Revision Process, http://www.usppf.com/pf/pub/data/v404/GEN_STIMULI_404_s201184.html (2014).
16. Blount, A.M., *Amphibole Content of Cosmetic and Pharmaceutical Talcs*, Environmental Health Perspectives, Vol. 94, pp. 225-230 (1991).
17. Boffetta, P., et al. *Cancer Risks Related to Electricity Production*. European Journal of Cancer. 1991; 7 (11); 1504-1519.

18. Boffetta, P., *Epidemiology of Peritoneal Mesothelioma: A Review*, Annals of Oncology 18, 985-990 (2007).
19. Boffetta P. *Health Effects of Asbestos Exposure in Humans: A Quantitative Assessment*. Med Lav 1998; 89,6:471-480.
20. British Thoracic Society Standards of Care Committee. *Statement on malignant mesothelioma in the United Kingdom*. Thorax 2001; 56:250-265.
21. Brown, D., et al., *Mortality Patterns Among Miners and Millers Occupationally Exposed to Asbestiform Talc*, Dusts and Diseases, 317-324 (1979).
22. *The Carcinogenicity of Chrysotile Asbestos - A Review*, 39 Industrial Health, 57, 63 (2001).
23. Cherrie JW, Tindall M, Cowie H. *Exposure and risks from wearing asbestos mitts*. Part Fibre Toxicol 2005, 2:5.
24. Churg, *Biological Effects of Asbestos, National Institutes of Health* (2/1/1973)
25. Churg, A. Warnock ML. *Asbestos and other ferruginous bodies.* Am J Pathol 1981; 102:447-56.
26. Coggiola, et al., *An Update of a Mortality Study of Talc Miners and Millers in Italy*, Am. J. Indus. Med. 44:63-69 (2003).
27. Committee on Nonoccupational Health Risks of Asbestiform Fibers, Board on Toxicology and Environmental Health Hazards and Commission on Life Sciences and National Research Council. *Asbestiform Fibers, Nonoccupational Health Risks* (1984)
28. *Consensus Report. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution.* Scand J Work Environ Health 1997;23:311 – 6.
29. *Consumer Patching Compounds And Artificial Emberizing Materials (Embers and Ash) Containing Respirable Free-Form Asbestos*, Federal Register, Vol. 42, No. 241 (December 13, 1977).
30. Cooke, W.E., *Pulmonary Asbestosis, The British Medical Journal*, pp. 1024-25. (December 3, *1927*)
31. Cralley, J., *Fibrous and Mineral Content of Cosmetic Talcum Products*, Amer. Ind. Hyg. Assoc. J 1968: July-August: 350-354.
32. Cramer DW, Welch WR, et al., *Ovarian Cancer and Talc*, Cancer 50, 372-376 (1982).
33. Dahlgren J, Peckham T. *Mesothelioma Associated With Use of Drywall Joint Compound: A Case Series and Review of Literature*, International Journal of Occupational and Environmental Health, 2012, V.18, No. 4, 337-343.
34. Davis J, et al., *Variations in the Carcinogenicity of Tremolite Dust Samples of Differing Morphology*, The Third Wave of Asbestos Disease: Exposure to Asbestos in Place, The New York Academy of Sciences, Vol 643 (1991).
35. Dement, et al., *Fiber Exposure During Use of Baby Powders, NIOSH* (1972)
36. Dement J, Pompeii L, Lipkus IM, Samsa GP. *Cancer Incidence Among Union Carpenters in New Jersey*, JOEM, Volume 45, Number 10 (October 2003).
37. Dodson, Ronald F., et al, *Asbestos Burden in Cases of Mesothelioma from Individuals from Various Regions of the United States*, Ultrastructural Pathology, 29:5, 415-433 (2005).

38. Dodson, Ronald F., et al., *Asbestos Fiber Length as Related to Potential Pathogenicity: A Critical Review,* 44 American Journal of Industrial Medicine, 291 (2003).
39. Dodson, Ronald F., *Analysis and Relevance of Asbestos Burden in Tissue, in Asbestos: Risk Assessment, Epidemiology and Health Effects.* 39,78-79 (Ronald F. Dodson and Samuel P. Hammar ed), 2006.
40. Dodson, Ronald F. and Hammar, S. Asbestos, Risk Assessment, Epidemiology, and Health Effects, Second Edition. (2011).
41. Doll, *Mortality from Lung Cancer in Asbestos Workers (1955)*
42. Dressen W, Dalla Valle JM, *The Effects of Exposure to Dust in Two Georgia Talc Mills and Mines*, Public Health Reports, Vol. 50, No. 5 (February 1, 1935).
43. Dunning, et al., *Mesothelioma Associated With Commercial Use of Vermiculite Containing Libby Amphibole*, 00 J. Envtl. Med. 00 (March 2012).
44. Egilman D, Fehnel C, Rankin Bohme S. *Exposing the "Myth" of ABC, "Anything But Chrysotile": A Critique of the Canadian Asbestos Mining Industry and McGill University Chrysotile Studies*. Am Journal Indus Med 44:540-557 (2003).
45. Egilman and Billings: *Abuse of Epidemiology: Automobile Manufacturers Manufacture a Defense to Asbestos Liability*, Int J Occup Environ Health 2005; 11:360-371.
46. Egilman D. *Fiber Types, Asbestos Potency, and Environmental Causation*. . Int J Occup Environ Health, Vol 15/No. 2, April/June 2009.
47. EPA: Guidance for Preventing Asbestos Disease Among Auto Mechanics. June 1986.
48. EPA: Health Assessment for Talc (March 1992)
49. EPA: National Inventory of Sources and Emissions: Asbestos – 1968. February 1970.
50. Finkelstein, M. *Asbestos Fiber Concentrations in the Lungs of Brake Workers: Another Look,* 52(6) Ann. Occup. Hyg. 455, 460 (2008).
51. Finkelstein, M., *Malignant Mesothelioma Incidence Among Talc Miners and Millers in New York State,* Am J Indust Med 55, 863-868 (2012).
52. Finkelstein MM, Meisenkothen C. *Malignant Mesothelioma among Employees of a Connecticut Factory that Manufactured Friction Materials Using Chrysotile Asbestos*. Ann Occ Hyg., Vol. 54, No. 6, pp. 692-696, 2010.
53. Finkelstein, M., *Pneumoconiosis and Malignant Mesothelioma in a Family Operated Metal Casting Business That Used Talc from New York State*, Am J Indust Med 56, 550-555 (2013).
54. Freeman M., Kohles S. *Assessing specific causation of mesothelioma following exposure to chrysotile asbestos-containing brake dust*, International Journal of Occupational and Environmental Health Vol 18, No. 4, 329 (2012).
55. Gamble, et al., *An Epidemiological-Industrial Hygiene Study of Talc Workers*, British Occupational Hygiene Society, 26:1-4 841-85 (1982).
56. Gibbs GW. *Fibre release from asbestos garments*. Ann Occup Hyg 1975, 18: 143-149.
57. Ghio, A, Roggli, V, *Talc Should Not Be Used for Pleurodesis in Patients with Nonmalignant Pleural Effusions*, Am J Respir Crit Care Med, Vol 164, No. 9, pp 1741 (2001).

58. Fujiwara, Hiroshi, et al. *An Autopsy Case of Primary Pericardial Mesothelioma in Arc Cutter Exposed to Asbestos through Talc Pencils*, 43 Industrial Health 346-350 (2005).
59. Gordon, et al., *Asbestos in commercial cosmetic talcum powder as a cause of mesothelioma in women*, 20 International Journal of Occupational and Environmental Health 4, 318-332 (2014).
60. Gordon, *Fertilizer Linked to Worker Death*, Spokesman-Review, June 20, 2001, at 85.
61. Greenberg M. *The Art of Perpetuating a Public Health Hazard*. JOEM Vol 47, No. 2, February 2005.
62. Gunter MR, Belluso E, Mottana A, *Amphiboles: Environmental and Health Concerns*, Reviews in Mineralogy & Geochemistry, Vol. 67, pp. 453-516 (2007).
63. Haque A, et al., *Is There Transplacental Transfer of Asbestos? A Study of 40 Stillborn Infants*, Pediatric Pathology & Laboratory Medicine, 16:877-897, 1996.
64. Hart, et al., *Evaluation of Asbestos Exposures During Firewood-Harvesting Simulations in Libby, MT, USA – Preliminary Data*, Ann. Occup. Hyg., Vol. 51, No. 8, pp. 1-7 (2007).
65. *High Levels of Asbestos Found In 3 Paints and 2 Talcums Here*, New York Times (June 16, 1972).
66. Hillerdal G. *Mesothelioma: new cases associated with non-occupational and low dose exposures.* Occup Environ Med 1999, 56:505-513.
67. Howard, Thomas, *Pneumoconiosis in a Vermiculite End-Product User*, Am. J. Indus. Med. 44:214-217 (2003).
68. Hueper, *Occupational & Non-occupational Exposures to Asbestos, Annals of the New York Academy of Sciences* (1965)
69. Hull, M., el at., *Mesothelioma Among Workers in Asbestiform Fiber-bearing Talc Mines in New York State*, Ann. Occup. Hyg., Vol. 46, Supplement 1, 132-135 (2002).
70. IARC Special Report: *A Review of Human Carcinogens -- Part C: metals, arsenic, dusts, and fibres.* The Lancet Volume 10, May 2009.
71. IARC Monographs on Evaluation of the Carcinogenic Risk of Chemicals to Humans, *Silica and Some Silicates,* Vol. 42 (1987)
72. Ilgren E, et al., *Critical reappraisal of Balangero chrysotile and mesothelioma risk*, Epidemiology Biostatistics and Public Health, Vol. 12, No. 1 (2015).
73. Ilgren E, et al., *Supplemental Data; Critical reappraisal of Balangero chrysotile and mesothelioma risk*, Epidemiology Biostatistics and Public Health, Vol. 12, No. 1 (2015).
74. Imbernon E, Marcharnd JL, Garras L, Goldberg M. *Evaluation quatitative du risqué de cancer du poumon et de mesotheliome pleural chez les mecaniciens de vehicules automobiles. Quantitative assessment of lung cancer and pleural mesothelioma among automobile mechanics*. Rev Epidemiol Sante Publique. 2005, 53:491-500.
75. Iwatsubo, Y., et al., *Pleural Mesothelioma: Dose-Response Relation at Low Levels of Asbestos Exposure in a French Population-Based Case-Control Study*, 148(2) Am. J. Epidemiology, 133, 136, 141 (1998).
76. Jama, *Asbestosis & Cancer of the Lung* (1949)

77. Joint Policy Committee, Societies of Epidemiology, *Position Statement on Asbestos from the Joint Policy Committee of the Societies of Epidemiology (JPC-SE)*, June 4, 2012.
78. Kanarek MS. *Mesothelioma from Chrysotile Asbestos: Update*. AEP Volume 21, No. 9. September 2011:688-697.
79. Kane M, et al., *Malignant Mesothelioma in Young Adults*, Cancer, Vol. 65(6), 1449-1455, 1990.
80. Karjalainen, Meurman, & Pukkala, *Four Cases of mesothelioma among Finish anthophyllite miners*, Occupational and Environmental Medicine, 51:212-215 (1994).
81. Keyes D.L., et al., *Exposure to Airborne Asbestos Associated with Simulated Cable Installation Above a Suspended Ceiling*, Am. Ind. Hyg. Assoc. J. 52 (November 1991).
82. Kim, Hyoung Ryoul, *Overview of Asbestos Issues in Korea*, 24 J Korean Med Sci 363-7 (2009).
83. Kim, et al., *Lung Cancer Probably Related to Talc Exposure: a Case Report, Industrial Healt*h, 51:228-231 (2013).
84. Kleinfeld, M., et al., *A Study of Workers Exposed to Asbestiform Minerals in Commercial Talc Manufacture*, Environ Research 6, 132-143 (1973).
85. Kleinfeld, M., *Mortality Among Talc Miners and Millers in New York State*, Arch Environ. Health, 14:663-667 (1967).
86. Kleinfeld, M., et al., *Talc Pneumoconiosis*, AMA Archives of Industrial Health, Vol. 12, pp 66-72 (1955).
87. Lacourt A., et al., *Attributable risk in men in two French case-control studies on mesothelioma and asbestos*. Eur. J. Epidemiol (2010) 25:799-806.
88. Lacourt A., et al., *Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma*. Thorax (2014) 0: 1-8.
89. Lamm, S.H., et al., *Similarities in Lung Cancer and Respiratory Disease Mortality of Vermont and New York State Talc Workers*, Epidemiology-Fibers, 1576-1581, (1988).
90. Landrigan PJ, Nicholson WJ, Suzuki Y, Ladou J. *The Hazards of Chrysotile Asbestos: A Critical Review*. Industrial Health 1999, 37, 271-280.
91. Landrigan PJ, *A Population of Children at Risk of Exposure to Asbestos in Place*, Annals New York Academy of Sciences, 283-286.
92. Landrigan PJ, Collegium Ramazzini, *Comments on the Causation of Malignant Mesothelioma: Rebutting the False Concept That Recent Exposures to Asbestos Do Not Contribute to Causation of Mesothelioma*, Annals of Global Health (2016)
93. Leigh J, Davidson P, Leigh H, Berry D. *Malignant Mesothelioma in Australia, 1945 – 2000*. Am Journal Indus Med, 41:188-201 (2002).
94. Lemen RA. *Chrysotile Asbestos as a Cause of Mesothelioma: Application of the Hill Causation Model*. Int J Occup Environ Health, Vol 10/No. 2, April/June 2004.
95. Lemen R: *Asbestos in Brakes: Exposure and Risk of Disease*. American Journal of Industrial Medicine, 45:229-237 (2004).

96. Li L, Sun T, Zhang X, Lai R, Li X, Fan X, Morinaga K. *Cohort Studies on Cancer Mortality Among Workers Exposed Only to Chrysotile Asbetsos: a Meta-analysis*. Biomedical and Environmental Sciences 17, 459-468 (2004).
97. Lieben J, et al., *Mesothelioma and Asbestos Exposure*, Arch. Environ. Health, Vol. 14 (April 1967).
98. Lightfoot, Kingston, Pooley, *An Examination of Italian Mine Samples and Relevant Powders, Department of Mineral Exploitation.* (September 8, 1972)
99. Lin S, et al. *Cause-Specific Mortality in Relation to Chrysotile Asbestos Exposure in a Chinese Cohort*. Journal of Thoracic Oncology, Volume XX, Number XX, XXX (2012).
100. Lockey, et al., *Pulmonary Changes After Exposure to Vermiculite Contaminated with Fibrous Tremolite*, Am. Rev. Respir. Dis. (1984).
101. Longo DK, Young RS, *Cosmetic Talc and Ovarian Cancer*, The Lancet, pp 349-351 (Aug 18, 1979).
102. Loomis D, Dement JM, Wolf SH, Richardson DB. *Lung Cancer Mortality and Fiber Exposures among North Carolina Asbestos Textile Workers*. Occup. Environ. Med. published online 11 Mar 2009; doi:10.1136/oem.2008.044362.
103. Lorimer WV, Rohl AN, Miller A, Nicholson WJ, Selikoff IJ. *Asbestos exposure of brake repair workers in the United States*. Mt. Sinai J Med 1976;43:207-18.
104. Lumley KP. *Asbestos dust levels inside firefighting helmets with chrysotile asbestos covers*. Ann Occup Hyg 1971, 14 (3); 285-286.
105. Lynch and Smith, Carcinoma of Lung in Asbestos- Silicosis (1935)
106. Madkour, *Environmental Exposure to Asbestos and the Exposure-Response Relationship with Mesothelioma*, E.Med.Health J. 15:25-38 (2009).
107. Markowitz S, *Asbestos-Related Lung Cancer and Malignant Mesothelioma of the Pleura: Selected Current Issues*, Semin Respir Crit Care Med, 36:334-346 (2015).
108. Mattenklott, M., TRANSLATION OF: "Asbestos in talc powders and soapstone – the present state" --- Asbest in Talkumpudern und Speckstein – heutige Situation. Gefahrstoffe – Reinhalt. Luft 67 (2007) no. 7/8 p. 287-291. (by courtesy of Springer-VDI-Verlag, Düsseldorf).
109. Mazurek, et al., Malignant Mesothelioma Mortality – United States, 1999-2015, Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report, 66(8);214-218 (March 3, 2017).
110. McDonald, et al., Malignant Mesothelioma in North America, 46 Cancer 7 (Oct. 1, 1980).
111. McDonald, et al., Mesothelioma and Asbestos Fiber Type: Evidence from Lung Tissue Analysis, Cancer, Vol. 63, No. 8, 1544-1547 (1989).
112. Merewether & Price, Report on Effects of Asbestos Dust on Lung & Dust Suppression in Asbestos Industry (1930)
113. Mesothelioma in a Brake Repair Worker, The Lancet. November 13, 1982.
114. Meurman, Kiviluoto, & Hakama, *Mortality and morbidity among the working population of anthophyllite asbestos miners in Finland*, British Journal of Industrial Medicine, 31:105-112 (1974).
115. Meurman, Pukkala, Hakama, *Incidence of Cancer among Anthophyllite asbestos miners in Finland*, Occupational and Environmental Medicine, 51:421-425 (1994).

116. Miller R., How Environmental Hazards in Childhood Have Been Discovered: Carcinogens, Teratogens, Neurotoxicants, and Others, Pediatrics 2004;113;945.
117. Millman N, Pneumonoconiosis Due To Talc In The Cosmetic Industry, Occup. Med., 4:391 (1947).
118. Mirabelli D, Cavone D, Merler E, Gennaro V, Romanelli A, Mensi C, Chellini E, Nicita C, Marinaccio A, Magnani C, Musti M. Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas. Occup Environ Med 2010;67:792e794. doi:10.1136/oem.2009.047019.
119. Mirabelli D, Cadum E, Mortality among patients with pleural and peritoneal tumors in Alta Valle di Susa, Epidemiol Prev., 26(6):284-6 (Nov-Dec 2002).
120. Newhouse and Thompson. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med 1965, 22 (4): 261-269.
121. New York Industrial Code Rule No. 12, adopted TLV. 1958
122. Nicholson WJ, Rohl A, Fischbein A, Selikoff IJ. Occupational and Community Asbestos Exposure from Wallboard Finishing Compounds. Bull. N.Y. Acad. Med., Vol. 51, No. 10, November 1975.
123. Nicholson WJ, Landrigan PJ. Asbestos: A Status Report. Current Issues in Public Health 1996, 2:118-123.
124. Nicholson WJ. The Carcinogenicity of Chrysotile Asbestos – A Review. Industial Health 2001, 39, 57-64.
125. Nynas, et al., *Cancer Incidence in Asbestos-Exposed Workers: An Update On Four Finnish Cohorts*, Finnish Institute of Occupational Health, 8:169-174 (2017).
126. Offermans N., et al., Occupational Asbestos Exposure and Risk of Pleural Mesothelioma, Lung Cancer, and Laryngeal Cancer in the Prospective Netherlands Cohort Study, J. Occ. Environ. Medicine, Vol. 56:1 (Jan. 2014).
127. Olsen, NJ, et al. Increasing Incidence of Malignant Mesothelioma After Exposure to Asbestos During Home Maintenance and Renovation. Med J Aust 2011; 195 (5): pp. 271-274.
128. Oury, T., Sporn, T., and Roggli, V, Pathology of Asbestos-Associated Diseases, Third Ed. Copyright 2014 – Chapters 3 and 8.
129. Paoletti, L., Evaluation by Electron Microscopy Techniques of Asbestos Contamination in Industrial, Cosmetic and Pharmaceutical Talcs, Regulatory Toxicology and Pharmacology, 4:222-235 (1984).
130. Pearce N, Checkoway H, Kriebel D: Bias in Occupational Epidemiology Studies, Occup Environ Med 2007;64:562-568. doi: 10.1136/aem.2006.026690.
131. Peretti, Luigi, Bulletin of the Subalpine Mining Association - Year III No. 3-4, "*Geology and Genesis of the Talc Deposits in the Pinerolese,*" September - December 1966.
132. Phillips, Murray, *Malignant Mesothelioma in a Patient with Anthophyllite Asbestos Fibres in the Lungs,* Oxford University Press, 54:412-416 (2010).
133. Piolatto, Giorgio, et al. An Update of cancer mortality among chrysotile asbestos miners in Balangero, northern Italy, 47 British Journal of Industrial Medicine 810-814 (1990).

134. Pira, et al., Mortality of Talc Miners and Millers from Val Chisone, Northern Italy, An Updated Cohort Study, Journal of Occupational and Environmental Medicine, Volume 59, Number 7 (July 2017).
135. Pooley, F., et al., Chemical and Physical Properties of British Talc Powders, Inhaled Particles, 639-646 (1975).
136. Porro FW, et al., Pneumoconiosis in the Talc Industry, Am. J. Roentgenology and Radium Therapy, Vol. 47, No. 4 (April 1942).
137. Price, B., Industrial-Grade Talc Exposure and the Risk of Mesothelioma, Crit Rev Toxicol 40(6), 513-530 (July 2010).
138. Ramazzini, Collegium, Asbestos is Still With Us: Repeat Call for A Universal Ban, 16 Int. J. Occup. Environ. Health, 351, 351-352 (2010).
139. Reid A, et al., Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis, Thorax (2014).
140. Rodelsperger K, Jockel KH, Pohlabein H, Romer W, Woitowitz HJ. Asbestos and Man-Made Vitreous Fibers as Risk Factors for Diffuse Malignant Mesothelioma: Results From a German Hospital-Based Case-Control Study. Am Journal of Ind Med, 39:262-275 (2001).
141. Roelofs, Cora, et al., Mesothelioma and employment in Massachusetts: Analysis of cancer registry data 1988 – 2003, American Journal of Industrial Medicine (2013)
142. Roggli, Victor, *Pathology of Human Asbestosis: A Critical Review*, Adv Pathol 2:31-60 (1989).
143. Roggli, Victor, et al., *Pulmonary Asbestos Body Counts and Electron Probe Analysis of Asbestos Body Cores in Patients with Mesothelioma, A Study of 25 Cases*, Cancer 50:2423-2432 (1982).
144. Roggli, Victor, et al., Tremolite and Mesothelioma, Ann. Occup. Hyg., Vol. 46, No. 5, pp. 447-453 (2002).
145. Rohl, AN, Asbestos in Talc, Enviro Health Persp, Vol 9, pp 129-132 (1974).
146. Rohl AN, Langer AM, Selikoff IJ, Nicholson WJ. Exposure to Asbestos in the Use of Consumer Spackling, Patching, and Taping Compounds. Science, 15 August 1975, Volume 189, pp. 551-553.
147. Rohl AN, Langer A, Fibrous Mineral Content of Consumer Talc-Containing Products, pp 394-403 (1979).
148. Rohl AN, Langer A, Identification and Quantitation of Asbestos in Talc, Enviro Health Persp, Vol 9, pp 95-109 (1974).
149. Rohl, A., et al. Asbestos Content of Dust Encountered in Brake Maintenance and Repair, 70 Proceedings of the Royal Society of Medicine, 32(1977).
150. Rohl, A., Langer, A., et al., Consumer Talcums and Powders: Mineral and Chemical Characterization, Journal of Toxicology and Environmental Health, 2:255-284 (1976).
151. Rohs, et al., Low-Level Fiber-induced Radiographic Changes Caused by Libby Vermiculite, A 25-Year Follow-up Study, 177 Am. J. Respir. Crit. Care. Med. 630 (2008).
152. Rolland, P., et al, "Risk of Pleural Mesothelioma: A French Population-Based Case-Control Study (1998-2006)." October 20, 2006/ Oral Session: Epidemiology II.

153. Rom, et al., *Malignant Mesothelioma From Neighborhood Exposure to Anthophyllite Asbesto*s, American Journal Of Industrial Medicine, 40:211-214 (2001).
154. Rubino, G.F., et al. Mortality Study of Talc Miners and Millers, Department of Occupational Medicine University of Torino Italy, presented at American Industrial Health Conference, San Francisco, California (April 14, 1975).
155. Rubino, G.F., et al. Mortality of chrysotile asbestos workers at the Balangero Mine, Northern Italy, 36 British Journal of Industrial Medicine 187-194 (1979).
156. Saitoh, Muto, Hachiya, Takizawa, Asbestos Body and Fiber Concentrations in Pathological Autopsy Tissues of Patients with Malignant Peritoneal Mesothelioma, Bull. Environ. Contam. Toxicol. 50:325-332 (1993).
157. Samimi BS, Williams AM. Occupational exposure to asbestos fibres resulting from use of asbestos gloves. Am Ind Hyg Assoc J 1981, 42:870-875.
158. Scancarello G, Romero R, Respiratory Disease as a Result of Talc Inhalation, J Occup Environ Med 38(6), 610-614 (June 1996).
159. Schepers, GW H and Durkan, TM, An Experimental Study of the Effects of Talc Dust on Animal Tissue, American Medical Association's Archives of Industrial Health, Vol. 12, Number 6. (December 1955)
160. Schulz RZ, Williams CR, Commercial Talc Animal and Mineralogical Studies, J Ind Hygiene and Toxicology, Vol. 24, No. 4 (1942).
161. Sebastien, Janson, Gaudichet, Hirsch and Bignon, Asbestos retention in Human Respiratory Tissues: Comparative Measurements in Lung Parenchyma and in Parietal Pleura, 30 IARC Sci. Pub., 237-246 (1980).
162. Silvertstein, M., Welch, L., Lemen, R. Developments in Asbestos Cancer Risk Assessment. Am Journal of Ind Med, 2009.
163. Smith AH, Wright CC. Chrysotile Asbestos is the Main Cause of Pleural Mesothelioma. Am J Indus Med 30:252-266 (1996).
164. Smith, D., Women and Mesothelioma, Chest, 122/6 1885-1886 (2002).
165. Srebo S, Roggli, V, Asbestos-Related Disease Associated with Exposure to Asbestiform Tremolite, Am J Int Med 26, 809-819 (1994).
166. Stayner LT. Canada's Asbestos International Expert Panel Report. J Occup Environ Med, 22.12.2008.
167. Suzuki Y, Kohyama N. Translocation of Inhaled Asbestos Fibers from the Lung to Other Tissues. Am J Indus Med., 19:701-704 (1990).
168. Suzuki, Y. & Kohyama, N. Translocation of Inhaled Asbestos Fibers from the Lung to Other Tissues, 19 Am. J. Ind. Med, 701 (1991).
169. Suzuki Y, Yuen SR. Asbestos Fibers Contributing to the Induction of Human Malignant Mesothelioma. Annals of the New York Academy of Science, Volume 982, December 2002.
170. Suzuki Y, Yuen SR, Ashley R. Short thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. Int J Hyg Environ-Health 208 (2005) 201-210.
171. Teschke, et al., Mesothelioma Surveillance to Locate Sources of Exposure to Asbestos, Can. J. Pub. Health (May – June 1997).
172. Thomas, *Lung Cancer Mortality among pottery workers in the United States*, Lyon International Agency for Research on Cancer (1990).

173. Thomas & Stewart, *Mortality From Lung Cancer and Respiratory Among Pottery Workers Exposed To Silica*, American Journal of Epidemiology, (1987).
174. Transactions – National Safety Council (NSC 3) (1934).
175. US Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, NIOSH. Control of Asbestos Exposure During Brake Drum Service. August 1989.
176. US Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, NIOSH. Report to Congress on Workers' Home Contamination Study Conducted Under the Workers' Family Protection Act (29 U.S.C. 671a). September 1995.
177. US Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, NIOSH. Asbestos Fibers and Other Elongate Mineral Particles: State of the Science and Roadmap for Research Revised Edition, 1-174 (2011).
178. U.S. Dept. of Labor: Working Safely with Asbestos in Clutch and Brake Linings. (posting).
179. U.S. Dept. of Labor, OSHA Directorate of Science, Technology and Medicine, Office of Science and Technology Assessment. Asbestos – Automotive Brake and Clutch Repair Work (bulletin).
180. U.S. Environmental Protection Agency – Region IX, *Response to the November 2005 National Stone, Sand & Gravel Association Report Prepared by the R.J. Lee Group, Inc. "Evaluation of EPA's Analytical Data from the El Dorado Hills Asbestos Evaluation Project,"* April 20, 2006.
181. Van Gosen, Bradley, The Geology of Asbestos in the United States and Its Practical Applications, Environmental & Engineering Geoscience, Vol. XIII, No. 1, February 2007. pp. 55-63.
182. Van Gosen, Bradley, et al., Using the geologic setting of talc deposits as an indicator of amphibole asbestos content, 45 Environmental Geology 920-939 (2004).
183. Van Horn, Earl C. *Talc Deposits of the Murphy Marble Belt*," NC Dept of Conservation and Development, Bulletin Number 56 (1948).
184. Vianna NJ. Non-Occupational Exposure to Asbestos and Malignant Mesothelioma in Females. The Lancet, May 20, 1978.
185. Vinikoor, et al., Exposure to Asbestos-Containing Vermiculite Ore and Respiratory Symptoms Among Individuals Who Were Children While the Mine Was Active in Libby, Montana, 118 Envtl. Health Perspectives 7 (July 2010).
186. Wagner, Diffuse Pleural Mesothelioma & Asbestos Exposure in the Northwestern Cape Province (1960)
187. Wagner, J.C., et al., Biological Effects of Tremolite, 45 Br. J. Cancer 352 (1982).
188. Ward, et al., Trees as reservoirs for amphibole fibers in Libby, Montana, Science of the Total Environment 367, pp. 460-465 (2006).
189. Webber, et al., Separation and Characterization of Respirable Amphibole Fibers from Libby, Montana, Inhalation Toxicology, 20:733-740 (2008).
190. Weill, H, et al., Health Effects of Tremolite, Am Rev Respir Dis 142, 1453-1458 (1990).

191. Welch, Laura, et al. Asbestos and Peritoneal Mesothelioma among College-educated Men, 11 International Journal of Occupational Environmental Health 254-258 (2005).
192. Welch, et al, Asbestos Exposure Causes Mesothelioma, But Not This Asbestos Exposure: An Amicus Brief to the Michigan Supreme Court, Int J Occup Environ Health 2007; 13:318-327.
193. Whitehouse, et al., Environmental Exposure to Libby Asbestos and Mesotheliomas, Am. J. Indus. Med. 50:877-880 (2008).
194. Wild C, Kleinjans J, Children and Increased Susceptibility to Environmental Carcinogens: Evidence or Empathy?, Cancer Epidemiology, Biomarkers & Prevention, 2003, Vol. 12; 1389-1394.
195. World Health Organization. Environmental Health Criteria 203: Chrysotile Asbestos. International Programme on Chemical Safety 1998. Geneva.
196. World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 93, Carbon Black, Titanium Dioxide, and Talc, Lyon, France (2010).
197. Yano, Wang, Wang, Wang, Lan, Cancer Mortality Among Workers Exposed to Amphibole-Free Chrysotile Asbestos, American J. Epid. 15, 154(6):538-43 (Sept. 2001).
198. Yano E, et al., Mesothelioma in a Worker Who Spun Chrysotile Asbestos at Home During Childhood, American Journal of Industrial Medicine, 52:282 – 287 (2009).

SELECTION OF SPECIFIC MATERIALS REVIEWED/RELIED ON:

A. Medical Records and Pathology Reports
   1. Rush University Medical Center – Pathology Reports (KO 0001-0006)
   2. Advocate Lutheran General Hospital – Medical Records (KO 0007-0497)
   3. Evanston Kellogg Cancer Center – Medical Records (KO 0498-0539)
   4. Medical Care Group – Medical Records (KO 0540-0617)
   5. Northshore Hospice – Medical Records (KO 0618-0626)
   6. NorthShore University Health System, Evanston Hospital – Path Records (KO 0627-0635)
   7. Rush University Medical Center – Medical Records (KO 0636-1134)
   8. Rush University Medical Center – Pathology Reports (KO 1135-1139)
   9. University Health System, Evanston Hospital – Medical Records (KO 1140-1171)

B. Deposition(s) of:
   1. Video Deposition of Harvey Kohr, dated February 27, 2017
   2. Video Deposition of Marilyn Mason, dated February 3, 20017
   3. Deposition of Elisa Kohr, dated March 30, 2017
   4. Deposition of Sheryl Salzman, dated March 31, 2017

C. Plaintiffs' Certified Responses to Defendant's Master Interrogatories

D. Death Certificate of Helene Kohr

E. Report of Dr. Steven Compton, MVA Scientific Consultants, September 13, 2017

F. Cosmetic Toiletry & Fragrance Association documents
G. Product and/or Source Talc Testing produced in litigation (see list below)
    1. October 15, 1957 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000001032-JNJAZ55_000001065.
    2. March 23, 1958 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000001341-JNJNL61_000001368.
    3. May 9, 1958 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000010804-JNJNL61_000010843.
    4. March 5, 1959 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000001114-JNJAZ55_000001120.
    5. July 31, 1959 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000000840-JNJAZ55_000000904.
    6. August 31, 1959 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000009799-JNJNL61_000009813.
    7. December 31, 1959 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000000797-JNJAZ55_000000839.
    8. January 31, 1960 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000002190-JNJAZ55_000002202.
    9. March 8, 1960 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000002203-JNJAZ55_000002219.
    10. April 12, 1960 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000001480-JNJNL61_000001484.
    11. July 11, 1961 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000001464-JNJNL61_000001471.

12. October 13, 1961 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000001014-JNJAZ55_000001018.
13. July 13, 1966 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000000049-JNJAZ55_000000051.
14. January 16, 1967 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000009897.
15. January 30, 1967 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Number JNJNL61_000009896.
16. April 17, 1967 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000001725-JNJNL61_000001726.
17. January 24, 1968 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000001489-JNJNL61_000001493.
18. October 31, 1968 – Johns-Manville Corporation testing, Body Talcum Powders – Petrographic Examination
19. June 30, 1971 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Number JNJAZ55_000006060.
20. July 7, 1971 – Colorado School of Mines Research Institute Report on Vermont Talc to Johnson & Johnson
21. July 19, 1971 – FDC Report on Bureau of Foods finding asbestos in Johnson & Johnson
22. July 29, 1971 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJMX68_000004646-JNJMX68_000004647.
23. February 1972 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Number JNJNL61_000001785.
24. May 15, 1972 – International Technical Service Manufacturing Letter for Body Powder
25. June 12, 1972 – ES Lab test of 1615 talc. WCD 1615 Talc Analysis (ASBESTOS)
26. June 12, 1972 – ES Lab test of Montana talc. WCD Talc Analysis (ASBESTOS)

27. July 14, 1972 – ES Lab test of Vermont talc. WCD Talc Analysis (ASBESTOS)
28. August 3, 1972 – Letter and final analytical results from S. Lewin to A. Weissler
29. August 24, 1972 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000003576-JNJAZ55_000003577.
30. September 30, 1972 – Lewin test of 1615 talc. WCD 1615 Talc Analysis (ASBESTOS)
31. October 27, 1972 – McCrone Examination of Johnson and Johnson's Baby Powder
32. October 27, 1972 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000005977-JNJAZ55_000005979.
33. December 8, 1972 – Pfizer test of 1615 talc. Letter to Clements from Stanley, Asbestos in Talc- findings from diffraction
34. April 27, 1973 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Number JNJAZ55_000017891.
35. May 8, 1973 – Proceedings of the Symposium on Talc, Washington DC by A. Langer
36. May 16, 1973 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000001892-JNJAZ55_000001898.
37. June 4, 1973 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Number JNJAZ55_000005083; JNJAZ55_000001587.
38. June 6, 1973 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Number JNJAZ55_000004643.
39. June 6, 1973 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Number JNJMX68_000006483.
40. July 31, 1973 – Memorandum from A. Weissler to R. Shaffner
41. August 28, 1973 – JM's TEM talc testing/ 14 samples. Memo to R.S. Lamar from V.E. Wolkodoff, Subject: "Determination of Chrysotile by TEM in Commercial Talcs."
42. October 19, 1973 – WCD Bristol-Myers Products Letter - Six samples of talc
43. December 10, 1973 – Round Robin test of Italian, Montana, Alabama, Vermont, and North Carolina talc. "Report of CTFA Method to Detect Chrysotile and Tremolite in Talc"

44. May 14, 1974 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJMX68_000004996-JNJMX68_000005044.
45. May 1, 1975 – RT Vanderbilt Company, Material Safety Data Sheet
46. 1976 - Briscese Lab Notebook. Colgate testing of Italian, Montana, North Carolina talc
47. March 1, 1976 - Dr. Shapiro and Dr. Langer "Memorandum for the Record of Telephone Conversation."
48. March 5, 1976 – Pfizer testing of two talc samples, Airspun fact powder [Code D070] and Airspun face powder [Code C-213].
49. December 1976 through June 1978 – Pfizer memos re testing talc samples to Coty Divisions of 1615 and 141 talcs
50. 1977 - McCrone Test of 1615 talc. Dates: 1970s-1980s
51. June 13, 1977 Minutes of CTFA Task Force on Round Robin Testing of Consumer Talcum Products for Asbestiform Amphibole Minerals
52. October 13, 1977 – ES Lab test of Vermont talc. WCD Talc Analysis (ASBESTOS)
53. January 24, 1978 – McCrone test of Vermont talc. WCD Talc Analysis (ASBESTOS)
54. May 26, 1978 – ES Lab test of Vermont talc. WCD Talc Analysis (ASBESTOS)
55. August 25, 1978 – McCrone test of Vermont talc. WCD Talc Analysis (ASBESTOS)
56. November 14, 1978 – ES Lab test of Vermont talc. WCD Talc Analysis (ASBESTOS)
57. February 13, 1979 – McCrone test of Vermont talc. WCD Talc Analysis (ASBESTOS)
58. March 5, 1979 – McCrone test of Vermont talc. WCD Talc Analysis (ASBESTOS)
59. November 1, 1979 – Pfizer memo re. "Routine Analysis of Coty Talc for Fibrous Tremolite" in 1615 and 141 talc samples
60. January 12, 1980 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000009483-JNJNL61_000009485.
61. September 17, 1980 – ES Lab test of Vermont talc. WCD Talc Analysis (ASBESTOS)
62. March 16, 1981 – McCrone Test of Monoblend for Colgate-Palmolive Co.
63. May 15, 1984 – Report of MSHA visit to Cyprus Industrial Minerals Company South Plainfield Mill
64. July 7, 1987 – ES Lab test of Vermont talc. WCD Talc Analysis (ASBESTOS)
65. October 19, 1988 – Due Diligence of for Windsor Minerals, Inc.
66. February 24, 2004 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex

County, Docket No.: MID-L-5973-16, Bates Numbers JNJI4T5_000004096-JNJI4T5_000004100.

67. July 9 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJAZ55_000005743-JNJAZ55_000005748.
68. Key to testing samples from Blount, A.M. (1991) Bates Number JNJNL61_000014437
69. Key to testing samples from Blount, A.M. (1991) Bates Number GUNTER00002233
70. Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000005343.
71. March 11, 1976 Colgate Laboratory Notebook Page 6490-2, signed by Pasquale Briscese – Analysis of sample "Cashmere Bouquet Mt. Sinai Study No. 1", Bates Numbers CPC-NB00000064
72. March 18, 1976 – Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJMX68_000009934-9936
73. May 4, 1976 - Protected Document, *Irma Verdolotti v. Brenntag North America, Inc., et al.*, Superior Court of New Jersey for Middlesex County, Docket No.: MID-L-5973-16, Bates Numbers JNJNL61_000035476-35498
74. October 27, 1976 Colgate Laboratory Notebook Page 6490-2, signed by Pasquale Briscese – Analysis of sample "Cashmere Bouquet Body Powder Code 4915 CX" ", Bates Numbers CPC-NB00000088
75. November 18, 1976 Documents related to McCrone's testing of sample 4915 (Finished Product), including: 11/1/1976 Enclosure Letter from Colgate to McCrone; 11/18/1976 results letter from McCrone to Colgate; and attached photomicrograph and SAED pattern", Bates Numbers McCRONE 0028, 0036-0039
76. February 5, 1974 Documents related to McCrone's testing of three talc samples (1 Cashmere Bouquet), including: 01/28/1974 Enclosure Letter from Colgate to McCrone; 02/05/1974 Results Letter from McCrone to Colgate; and attached photomicrograph and SAED pattern", Bates Numbers McCRONE 0168, 0170, 0172-173
77. January 27, 1976 Colgate Laboratory Notebook Pages 6164-85 through 6164-87, signed by Pasquale Briscese – Analysis of samples "Cashmere Bouquet FDA Sample," "Cashmere Bouquet Body Powder UCC11," and "Cashmere Bouquet Body Powder UCC4" ", Bates Numbers CPC-NB00000055-57
78. March 12, 1976 Colgate Laboratory Notebook Page 6490-2, signed by Pasquale Briscese – Analysis of sample "Cashmere Bouquet Body Talc 4 oz. No Code (with Deocin) UCC6 Container" ", Bates Numbers CPC-N800000065

79. March 25, 1976 Colgate Laboratory Notebook Page 6490-2, signed by Pasquale Briscese – Analysis of sample "DCST 76-1360 Cashmere Bouquet Talc from CTFA" ", Bates Numbers CPC-NB00000066
80. April 27, 1984 Documents related to McCrone's testing of six talc samples (3 Cashmere Bouquet), including: 01/24/1984 Enclosure Letter from Colgate to McCrone; and 04/27/1984 Results Letter from McCrone to Colgate", Bates Numbers McCRONE 0223, 0221
81. March 8, 1976 Pfizer Chemical Testing form – two samples of Coty Airspun Face Powder, Bates Numbers PFE-Hug00007094
82. March 12, 1976 CTFA Memorandum from Estrin to Curry re Coty testing